Eikon Ther­a­peu­tics rais­es $351M Se­ries D as lead drug starts Phase 3

One of biotech’s best-fund­ed star­tups has just raised a huge new round to take its lead drug in­to fi­nal-stage test­ing.

On Wednes­day, Eikon Ther­a­peu­tics an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER